Siegfried Holding AGXSWX:SFZN +1.60%94 EBITDA Margin % is 25.65% as of Dec. 2025, which is 48% above its 10-year median of 17.29. GuruFocus rates XSWX:SFZN with a GF Score™ of 94/100 and a GF Value™ of CHF91.94 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Siegfried Holding AG ranks better than 75.81% on this metric.
Siegfried Holding AG (XSWX:SFZN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Siegfried Holding AG EBITDA Margin % Related Terms
Siegfried Holding AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Siegfried Holding AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SFZN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siegfried Holding AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Siegfried Holding AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siegfried Holding AG (XSWX:SFZN) has a EBITDA Margin % of 25.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Siegfried Holding AG and its competitors. This is 48% above median its historical median of 17.29. Over the past decade, Siegfried Holding AG's EBITDA Margin % has ranged from 12.73 to 25.06. According to the industry distribution chart, Siegfried Holding AG ranks #231 out of 955 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Siegfried Holding AG's EBITDA Margin % too high?
Siegfried Holding AG's current EBITDA Margin % of 25.65% is 48% above median its 10-year median of 17.29. Over the past 10 years, this metric has ranged from a low of 12.73 to a high of 25.06. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Siegfried Holding AG's value of 25.65% is 107% above this industry median. Based on the distribution chart, Siegfried Holding AG ranks #231 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Siegfried Holding AG has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siegfried Holding AG's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Siegfried Holding AG ranks #231 out of 955 companies for EBITDA Margin %. This places Siegfried Holding AG in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Siegfried Holding AG's value of 25.65% is 107% above this benchmark. Historically, Siegfried Holding AG's own EBITDA Margin % has ranged from 12.73 to 25.06 over the past decade. While the company's 10-year median is 17.29 vs. the industry median of 12.39, Siegfried Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siegfried Holding AG's current EBITDA Margin % of 25.65% is 107% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Siegfried Holding AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siegfried Holding AG's current EBITDA Margin % is 25.65%, which is 48% above median its own 10-year median of 17.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siegfried Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Siegfried Holding AG (XSWX:SFZN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF91.94, compared to a current price of CHF69.65 — trading 24.2% below its estimated fair value. The current EBITDA Margin % is 25.65%, which is 48% above median its 10-year median of 17.29 and 107% above the Drug Manufacturers industry median of 12.39. Siegfried Holding AG's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Siegfried Holding AG (XSWX:SFZN), the current EBITDA Margin % is 25.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siegfried Holding AG (XSWX:SFZN) Overvalued in 2026?
Based on GuruFocus' analysis, Siegfried Holding AG stock appears to be undervalued.
The current stock price of CHF69.65 is trading 24.2% below its estimated GF Value™ of CHF91.94.
GuruFocus considers Siegfried Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SFZN:
EBITDA Margin %: 25.65% (48% above median its 10-year median of 17.29)
GF Value™: CHF91.94 vs. price of CHF69.65 (24.2% below fair value)
Industry Position: 107% above the Drug Manufacturers median (#231 of 955)
No single metric tells the full story. See the XSWX:SFZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
94GF Score
Get the complete analysis for XSWX:SFZN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SFZN has been successfully added to your 
